Natco Pharma Ltd
NSE:NATCOPHARM

Watchlist Manager
Natco Pharma Ltd Logo
Natco Pharma Ltd
NSE:NATCOPHARM
Watchlist
Price: 1 371.5 INR -1.23% Market Closed
Market Cap: 245.6B INR
Have any thoughts about
Natco Pharma Ltd?
Write Note

Natco Pharma Ltd
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Natco Pharma Ltd
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Natco Pharma Ltd
NSE:NATCOPHARM
Other Current Liabilities
â‚ą4.9B
CAGR 3-Years
51%
CAGR 5-Years
18%
CAGR 10-Years
15%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Current Liabilities
â‚ą57.8B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Current Liabilities
â‚ą25.4B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Current Liabilities
â‚ą93.2B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
15%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Current Liabilities
â‚ą10.1B
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Current Liabilities
â‚ą8.4B
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Natco Pharma Ltd
Glance View

Market Cap
245.6B INR
Industry
Pharmaceuticals

Nestled in the bustling business corridors of Hyderabad, India, Natco Pharma Ltd. has cultivated a strong presence in the pharmaceutical industry over the decades. Founded in 1981, the company initially ventured into the local market, gradually establishing itself as a critical player through specialization in complex chemistry and niche therapeutic sectors. The company's primary focus is on the development and manufacturing of generic drugs, specifically in the oncology and neurology segments. In these high-stakes areas, Natco leverages its robust research and development capabilities to produce affordable alternatives to expensive branded medications, thereby ensuring access to critical treatments for broader populations. Natco Pharma's business acumen extends beyond merely producing generics. It is adept at capitalizing on patent expirations, quickly launching generics and biosimilars in both domestic and international markets. The company has strategically focused operations in markets such as the United States and Europe, where it partners with local distributors to reach end-users. Through a combination of manufacturing efficiencies and strategic partnerships, Natco is able to maintain competitive pricing, thus enhancing its market penetration and revenue generation. Its integrated business model, combining in-house R&D, manufacturing, and distribution, ensures that Natco remains a formidable player, bridging the gap between complex pharmaceuticals and cost-effective healthcare solutions.

NATCOPHARM Intrinsic Value
721.24 INR
Overvaluation 47%
Intrinsic Value
Price

See Also

What is Natco Pharma Ltd's Other Current Liabilities?
Other Current Liabilities
4.9B INR

Based on the financial report for Sep 30, 2024, Natco Pharma Ltd's Other Current Liabilities amounts to 4.9B INR.

What is Natco Pharma Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
15%

Over the last year, the Other Current Liabilities growth was 81%. The average annual Other Current Liabilities growth rates for Natco Pharma Ltd have been 51% over the past three years , 18% over the past five years , and 15% over the past ten years .

Back to Top